Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

NCT06886074 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Measurable Residual Disease (MRD)

Interventions

DRUG: Short course of blinatumomab

Sponsor

Hospital Universitario Dr. Jose E. Gonzalez